226 related articles for article (PubMed ID: 32338754)
1. Assessment of Expected Out-of-Pocket Spending for Rheumatoid Arthritis Biologics Among Patients Enrolled in Medicare Part D, 2010-2019.
Erath A; Dusetzina SB
JAMA Netw Open; 2020 Apr; 3(4):e203969. PubMed ID: 32338754
[TBL] [Abstract][Full Text] [Related]
2. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
[TBL] [Abstract][Full Text] [Related]
3. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.
Yazdany J; Dudley RA; Chen R; Lin GA; Tseng CW
Arthritis Rheumatol; 2015 Jun; 67(6):1474-80. PubMed ID: 25900105
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
[TBL] [Abstract][Full Text] [Related]
5. Reducing out-of-pocket cost barriers to specialty drug use under Medicare Part D: addressing the problem of "too much too soon".
Doshi JA; Li P; Pettit AR; Dougherty JS; Flint A; Ladage VP
Am J Manag Care; 2017 Mar; 23(3 Suppl):S39-S45. PubMed ID: 29648739
[TBL] [Abstract][Full Text] [Related]
6. Association Between the Percentage of US Drug Sales Subject to Inflation Penalties and the Extent of Drug Price Increases.
Dickson S
JAMA Netw Open; 2020 Sep; 3(9):e2016388. PubMed ID: 32915237
[TBL] [Abstract][Full Text] [Related]
7. Five-year impact of Medicare Part D coverage gap reform on drug expenditures and utilization.
Park J; Look KA
Health Serv Res; 2022 Feb; 57(1):56-65. PubMed ID: 33870486
[TBL] [Abstract][Full Text] [Related]
8. Medicare Part D and Cost-Sharing for Antiretroviral Therapy and Preexposure Prophylaxis.
Tseng CW; Dudley RA; Chen R; Walensky RP
JAMA Netw Open; 2020 Apr; 3(4):e202739. PubMed ID: 32286656
[TBL] [Abstract][Full Text] [Related]
9. Closing the Part D Coverage Gap and Out-of-Pocket Costs for Multiple Sclerosis Drugs.
Hartung DM; Johnston KA; Bourdette DN; Chen R; Tseng CW
Neurol Clin Pract; 2021 Aug; 11(4):298-303. PubMed ID: 34484929
[TBL] [Abstract][Full Text] [Related]
10. Variation in Prescription Drug Coverage Enrollment Among Vulnerable Beneficiaries With Glaucoma Before and After the Implementation of Medicare Part D.
Blumberg DM; Prager AJ; Liebmann JM
JAMA Ophthalmol; 2016 Feb; 134(2):212-20. PubMed ID: 26720853
[TBL] [Abstract][Full Text] [Related]
11. Use and Spending for Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among US Medicare Beneficiaries.
Yazdany J; Tonner C; Schmajuk G
Arthritis Care Res (Hoboken); 2015 Sep; 67(9):1210-1218. PubMed ID: 25776035
[TBL] [Abstract][Full Text] [Related]
12. Medicare Part D Payments for Topical Steroids: Rising Costs and Potential Savings.
Song H; Adamson A; Mostaghimi A
JAMA Dermatol; 2017 Aug; 153(8):755-759. PubMed ID: 28453645
[TBL] [Abstract][Full Text] [Related]
13. Trends in Prices, Market Share, and Spending on Self-administered Disease-Modifying Therapies for Multiple Sclerosis in Medicare Part D.
San-Juan-Rodriguez A; Good CB; Heyman RA; Parekh N; Shrank WH; Hernandez I
JAMA Neurol; 2019 Nov; 76(11):1386-1390. PubMed ID: 31449293
[TBL] [Abstract][Full Text] [Related]
14. The Effect of Medicare Part D on Prescription Drug Spending and Health Care Use: 6 Years of Follow-up, 2007-2012.
Park T; Jung J
J Manag Care Spec Pharm; 2017 Jan; 23(1):5-12. PubMed ID: 28025927
[TBL] [Abstract][Full Text] [Related]
15. Medicare Beneficiaries Face Growing Out-Of-Pocket Burden For Specialty Drugs While In Catastrophic Coverage Phase.
Trish E; Xu J; Joyce G
Health Aff (Millwood); 2016 Sep; 35(9):1564-71. PubMed ID: 27605634
[TBL] [Abstract][Full Text] [Related]
16. Mind the Gap: Why Closing the Doughnut Hole Is Insufficient for Increasing Medicare Beneficiary Access to Oral Chemotherapy.
Dusetzina SB; Keating NL
J Clin Oncol; 2016 Feb; 34(4):375-80. PubMed ID: 26644524
[TBL] [Abstract][Full Text] [Related]
17. Spending on World Health Organization essential medicines in Medicare Part D, 2011-15: retrospective cost analysis.
Li DG; Najafzadeh M; Kesselheim AS; Mostaghimi A
BMJ; 2019 Jul; 366():l4257. PubMed ID: 31315833
[TBL] [Abstract][Full Text] [Related]
18. Association of Drug Rebates and Competition With Out-of-Pocket Coinsurance in Medicare Part D, 2014 to 2018.
Lakdawalla D; Li M
JAMA Netw Open; 2021 May; 4(5):e219030. PubMed ID: 33950205
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance.
DiStefano MJ; Kang SY; Parasrampuria S; Anderson GF
JAMA Health Forum; 2023 May; 4(5):e231090. PubMed ID: 37234016
[TBL] [Abstract][Full Text] [Related]
20. The Impact of Medicare Part D on the Proportion of Out-of-Pocket Prescription Drug Costs Among Older Adults With Diabetes.
Choi YJ; Jia H; Gross T; Weinger K; Stone PW; Smaldone AM
Diabetes Care; 2017 Apr; 40(4):502-508. PubMed ID: 27803119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]